Atara Biotherapeutics Inc (ATRA) Given Average Rating of “Buy” by Brokerages
Atara Biotherapeutics Inc (NASDAQ:ATRA) has been given an average rating of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $22.67.
ATRA has been the subject of a number of research reports. Goldman Sachs Group reiterated a “neutral” rating and issued a $20.00 price target on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Canaccord Genuity reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. Jefferies Group reiterated a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, October 5th. Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target for the company in a research note on Wednesday, January 3rd. Finally, ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th.
Shares of Atara Biotherapeutics (ATRA) traded up $1.45 during midday trading on Friday, hitting $22.15. The stock had a trading volume of 652,200 shares, compared to its average volume of 1,142,237. Atara Biotherapeutics has a twelve month low of $11.80 and a twelve month high of $23.00. The stock has a market capitalization of $670.36, a price-to-earnings ratio of -6.38 and a beta of 1.27.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). equities research analysts predict that Atara Biotherapeutics will post -4 earnings per share for the current fiscal year.
In other Atara Biotherapeutics news, CFO John Mcgrath sold 32,000 shares of Atara Biotherapeutics stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $20.00, for a total value of $640,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Isaac E. Ciechanover sold 4,400 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $13.47, for a total value of $59,268.00. Following the completion of the transaction, the chief executive officer now owns 737,767 shares of the company’s stock, valued at $9,937,721.49. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 121,788 shares of company stock valued at $2,194,934. 16.20% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of the business. Neuberger Berman Group LLC boosted its stake in Atara Biotherapeutics by 15.2% in the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after acquiring an additional 147,061 shares during the period. Perceptive Advisors LLC acquired a new position in Atara Biotherapeutics in the third quarter valued at approximately $581,000. Artal Group S.A. boosted its position in shares of Atara Biotherapeutics by 20.0% during the third quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $9,930,000 after buying an additional 100,000 shares during the period. SG Americas Securities LLC acquired a new position in shares of Atara Biotherapeutics during the third quarter worth approximately $142,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Atara Biotherapeutics during the third quarter worth approximately $170,000. Institutional investors own 85.61% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.